DS
ABCL icon

David Shaw’s AbCellera Biologics ABCL Stock Holding History

David Shaw’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-224,600
Closed -$3.21M – 5477
2021
Q4 		$3.21M Hold
224,600
– – ﹤0.01% 2875
2021
Q3 		$4.5M Buy
+224,600
New +$3.97M ﹤0.01% 2203

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

David Shaw's ABCL Position: Q2 2026 in Review

David Shaw opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 45,431 shares worth $357K. The stake represents ﹤0.01% of the portfolio and ranks #4340 among its holdings. This is a return to the name: David Shaw previously reported a position in ABCL as recently as Q4 2025.

David Shaw first reported a position in ABCL in Q3 2021 and has held it in 17 quarters since. The position peaked at $27.4M in Q3 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • David Shaw held 45,431 shares of AbCellera Biologics worth $357K as of Q2 2026.
  • AbCellera Biologics was a new David Shaw position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4340 holding.
  • David Shaw first reported a position in AbCellera Biologics in Q3 2021 and has held it in 17 quarters since.
  • David Shaw's AbCellera Biologics position peaked at $27.4M in Q3 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.